Although angiogenesis is a hallmark feature of asthmatic inflammatory responses, therapeutic anti-angiogenesis interventions have received little attention. Objective: Assess the effectiveness of anti-angiogenic Sn2 lipase-labile prodrugs delivered via αvβ3-micellar nanotherapy to suppress microvascular expansion, bronchial remodeling, and airway hyper-responsiveness in Brown Norway rats exposed to serial house dust mite (HDM) inhalation challenges. Results: Anti-neovascular effectiveness of αvβ3-mixed micelles incorporating docetaxel-prodrug (Dxtl-PD) or fumagillin-prodrug (Fum-PD) were shown to robustly suppress neovascular expansion (p<0.01) in the upper airways/bronchi of HDM rats using simultaneous 19 F/ 1 H MR neovascular imaging, which was corroborated by adjunctive fluorescent microscopy. Micelles without a drug payload (αvβ3-No-Drug) served as a carrier-only control. Morphometric measurements of HDM rat airway size (perimeter) and vessel number at 21d revealed classic vascular expansion in control rats but less vascularity (p<0.001) after the anti-angiogenic nanotherapies. CD31 RNA expression independently corroborated the decrease in airway microvasculature. Methacholine (MCh) induced respiratory system resistance (Rrs) was high in the HDM rats receiving αvβ3-No-Drug micelles while αvβ3-Dxtl-PD or αvβ3-Fum-PD micelles markedly and equivalently attenuated airway hyper-responsiveness and improved airway compliance. Total inflammatory BAL cells among HDM challenged rats did not differ with treatment, but αvβ3 + macrophages/monocytes were significantly reduced by both nanotherapies (p<0.001), most notably by the αvβ3-Dxtl-PD micelles. Additionally, αvβ3-Dxtl-PD decreased BAL eosinophil and αvβ3 + CD45 + leukocytes relative to αvβ3-No-Drug micelles, whereas αvβ3-Fum-PD micelles did not. Conclusion: These results demonstrate the potential of targeted anti-angiogenesis nanotherapy to ameliorate the inflammatory hallmarks of asthma in a clinically relevant rodent model.
Introduction
Asthmatic symptoms like bronchial hyper-responsiveness and overall reduced lung function reflect the underlying structural changes to the airway wall due to chronic inflammation. [1] Among the notable structural remodeling features of asthmatic airways is the long-recognized expansion of the bronchial vascular bed. Earlier research showed that alterations in bronchial blood flow or capacity in asthmatic patients were quantitatively reflected as changes in airway temperature. These changes in
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International Publisher airway temperature were unrelated to cardiac output or pulmonary blood flow, suggesting that they were associated with vascular expansion within the bronchial circulation. [2] [3] [4] [5] [6] Systemic vascular expansion in the lung is associated with macrophage activation, elaborating pro-angiogenic chemokines that stimulate neovascular expansion. [7, 8] Anti-inflammatory systemic or inhaled corticosteroids are critical therapeutic drugs used in the acute and chronic management of asthma patients, which at higher doses elicit pleiotropic pharmacologic vascular remodeling effects including local vasoconstriction and inhibition of the production of pro-angiogenic cytokines and chemokines. [9] [10] [11] [12] Neovastat, an anti-inflammatory marine cartilage derivative, suppressed airway inflammation associated with reductions in vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-2α (HIF-2α) expression in murine lung tissue in ovalbumin-sensitized mice. [13] Despite the close interrelationship of airway inflammation and increased microvascularity, anti-angiogenesis treatment, such as anti-VEGF therapy, has not been considered, perhaps because such blockades can be circumvented by alternative pro-angiogenic factors and endothelial signaling pathways.
Fumagillin is a highly potent anti-angiogenic mycotoxin that inhibits methionine aminopeptidase-2 in proliferating endothelial cells leading to apoptosis. [14, 15] In its stabilized water soluble form, designated TNP-470, it had anecdotal benefit in cancer patients but at the systemic doses required patients experienced mild to moderate neurocognitive side-effects. [16] [17] [18] [19] [20] [21] Native fumagillin incorporated into the lipid encapsulated αvβ3-targeted nanoparticles markedly lowered the effective dose in preclinical cancer [22] and rheumatoid arthritis [23] models, which was further reduced when included as an Sn2 lipase labile phospholipid prodrug. [24, 25] Paclitaxel, which interacts with tubulin also has anti-angiogenic benefit. [26] However, the off-target adverse profile of taxanes precludes their general systemic use as an anti-angiogenic therapeutic for asthma. Unlike native fumagillin, hydrophobic taxanes were not effectively retained in lipid encapsulated αvβ3-targeted nanoparticles during circulation except when modified into an Sn2 lipase labile prodrug. [27] Importantly, at an effective anti-angiogenic drug level of taxane administered as α v β 3 -targeted Sn2 docetaxel prodrug nanoparticles in the Vx2 rabbit cancer model, Abraxane dosed iv was ineffective. [27] In the present study, lipase labile phospholipid prodrug forms of fumagillin (Fum-PD) or docetaxel (Dxtl-PD) were incorporated into lipid-based micelles for targeted drug delivery in the context of asthma to determine if anti-angiogenesis nanotherapy could offer a new therapeutic approach to this serious disease. [25, [27] [28] [29] In general, lipase labile prodrugs inactivate chemotherapeutic compounds and prevent premature drug-loss from the nanoparticle during circulation. Sensitive functional groups of drugs are sequestered within the hydrophobic acyl membrane compartment and protected from the surrounding water milieu. [30] Lipid prodrugs are delivered by a mechanism termed "contact-facilitated drug delivery" (CFDD). [31] For CFDD the targeted cell surface receptor, e.g., αvβ3, is used as a "mooring" that allows the lipid nanoparticle surface to form an irreversible hemifusion complex with the target cell membrane. [32, 33] The prodrugs transfer spontaneously into the target cell outer and then inner membranes. The continuity of the inner cell membrane with intracellular membranes, except mitochondria, distributes the prodrugs throughout the cellular compartments. Within the cell a myriad of intracellular lipases can cleave the Sn2 ester of the lipid backbone, liberating and reactivating the compound within the cytosol. Direct targeting of proliferating neoendothelial cells with αvβ3-targeted Fum-PD or Dxtl-PD nanoparticles induces apoptosis. [24] In this proof of concept study, the impact of anti-neovascular therapy was evaluated as a therapeutic regimen for asthma in a clinically relevant animal model. The temporal and spatial distribution of angiogenesis, vascularity, and airway reactivity in a Brown Norway rat model following serial allergen challenges with house dust mite (HDM) was recently characterized by Wagner et al. [34] Utilizing this model, the overarching objectives of this proof-of-concept study were: 1) to confirm the anti-angiogenic efficacy in asthma of αvβ3-targeted Fum-PD or Dxtl-PD micelles using MR simultaneous dual 19 F/ 1 H neovascular molecular imaging (3T); 2) to assess the impact of anti-angiogenesis therapy on airway hyper-reactivity and compliance response to methacholine challenge; 3) to delineate the impact of anti-angiogenesis treatment on airway vascular morphology and structural remodeling; and 4) to characterize the treatment effects on bronchial alveolar lavage cell numbers and type.
Methods

Preparation of Sn2 lipase labile fumagillin prodrug
A modified synthesis of the Sn2 prodrug was developed and accomplished in two steps [29] : 1) saponifying fumagillin dicyclohexylamine salt to fumagillol, and 2) esterifying the product with 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzPC). [29] (Figure 1A ) Briefly, fumagillin dicyclohexylamine salt (NCI) in 0.1N NaOH was stirred at ambient temperature (4h). The reaction mixture was extracted with ethyl ether (3X) and dried with anhydrous Na2SO4. After filtering the Na 2 SO 4 the ether was evaporated to a yellow oil (yield ~60%). The final structure of fumagillol was confirmed by MS.
A solution of 1-hexadecyl-2-azelaoyl-snglycero-3-phosphocholine (Paz-PC, Avanti Polar Lipids) 1mM, 4-dimethylaminopyridine (DMAP)(5X) and N,N'-dicyclohexyl-carbodiimide (DCC) (5X) was added to 1mM fumagillol in minimal dry chloroform. The reaction mixture was stirred overnight at ambient temperature then passed over a short pad of silica gel using EtOAc/n-hexane (1:1). The filtered solvent was removed in vacuo, and the oil residue was purified by column chromatography on SiO2 using EtOAc/n-hexane for elution to yield the fumagillol prodrug (Fum-PD) compound as a pale yellowish solid (yield: 54%). Mass spectroscopy (MS) confirmed the final synthetic structure: m/z [C49H88NO13P, calculated mass= 929.60, observed= 930].
Preparation of Sn2 lipase labile docetaxel prodrug
For the present research modified synthesis of docetaxel prodrug was developed. Docetaxel (Sigma Aldrich) dissolved in dimethylformamide (DMF) 0.02 mmole/ml was combined with Paz-PC in chloroform (0.02 mmole/ml) then carbodiimide (DCC) / dimethylaminopyridine (DMAP) on silica was added. The mixture was incubated at room temperature overnight then filtered. The DMF was dried in vacuo to a solid. (Figure 1B and provided coupled to phosphatidylethanolamine through a polyethylene glycol2000 spacer (α ν β 3 -PEG-PE, Kereos, Inc., Figure  1C ). The antagonist was initially characterized as the 111 In-DOTA conjugate RP478 and cyan 5.5 homologue TA145. [35] PFC nanoparticles present ~300 ligands/particle with an IC 50 of 50 pM for the Mn 2+ -activated α v β 3 -integrin. [36] The homing high specificity of α ν β 3 -nanoparticles (>150 nm nominal diameter) was previously characterized using microscopic histology of Matrigel™ plugs implanted into Rag1 tm1Mom Tg (Tie-2-lacZ)182-Sato and C57Bl/6 mice [37] , using photoacoustic molecular imaging of neovascular sprouting in a Matrigel™ plug model in rats [38] , and in an ischemic left pulmonary artery ligation (LPAL) model of bronchial angiogenesis induction in rodents.
[39] Robust reproducibility of serial targeting and MR molecular imaging within individual rabbits bearing Vx2 tumors over approximately one week was also reported. [40] Synthesis of α v β 3 -integrin targeted therapeutic micelles Therapeutic mixed micelles were prepared by microfluidization using 20% (v/v) polysorbate 80 (NOF America), 2.0% (w/v) of a surfactant co-mixture, and 1.7% (w/v) glycerin suspension in carbonate buffer (pH 6.5). The surfactant co-mixture of nanoparticles included: 97.8 mole% lecithin and 0.2 mole% of αvβ3-PEG-PE, and 2 mole% of Fum-PD or Dxtl-PD. Drug concentrations of the therapeutic micelles were equimolar (0.5mM). AlexaFluor™ or rhodamine dyes for fluorescent microscopy were coupled to PEG 2000 -PE lipid anchors (0.6 mole%) and included in the surfactant co-mixture at the equimolar expense of lecithin for fluorescent microscopy. "No-Drug" nanoparticles excluded the 2 mole% of Fum-PD or Dxtl-PD, which was replaced by lecithin. Surfactant components were combined with the polysorbate, buffer, and glycerin with pH adjusted to 6.5, and the mixtures were homogenized at 20,000 psi for 4 minutes. The micelles were preserved under inert gas in sterile sealed vials until use.
Synthesis of α v β 3 -integrin targeted perfluorocarbon nanoparticles for MR imaging
Phospholipids-encapsulated perfluorocarbon (PFC) nanoparticles (NP) for neovascular MR molecular imaging were prepared as a microfluidized suspension of 20% (v/v) perfluoroctylbromide (PFOB, Exfluor Inc., Round Rock, TX), 2.0% (w/v) of a surfactant co-mixture, and 1.7% (w/v) glycerin in pH 6.5 carbonate buffer as described above. The surfactant co-mixture of nanoparticles included: ~ 99.8 mole% lecithin and 0.2 mole% of αvβ3-PEG-PE. Dyes, e.g. AlexaFluor™ or rhodamine, were coupled to PEG 2000 -PE lipid anchors (0.6 mole%) and included in the surfactant co-mixture at the equimolar expense of lecithin for fluorescent microscopy. Typical particle size determined by dynamic light scattering was 214 ± 20 nm with a polydispersity index of 0.15 ± 0.5 and zeta potential, (ζ) of 23 ± 12 mV (Brookhaven ZetaPlus, Brookhaven Instruments Corporation).
MR neovascular imaging response to α v β 3 -targeted Fum-PD and Dxtl-PD nanotherapy
Male Brown Norway rats (BN, Charles River, 100 g) were administered house dust mite allergen (HDM, Der p 1; 100 µg/100µl challenge, Greer Laboratories) by intranasal inspiration, as previously reported [34] on days 0, 5 and 7 followed by i.v. α v β 3 -No-Drug (n=6), α v β 3 -Fum-PD (n=6) or α v β 3 -Dxtl-PD (n=6) on days 6 and 8 (35µl, 0.7 µmole/kg/dose to offset anticipated transbiliary losses in rodents). [41] All animals were studied using simultaneous dual 19 F/ 1 H MR neovascular imaging at 3T (Achieva 3T, Philips Healthcare, Andover, MA). Animal protocols were approved by the Johns Hopkins and Washington University Animal Care and Use Committees.
On day 10, 2 days following the last anti-angiogenesis nanotherapy, all HDM treatment groups were administered αvβ3-PFOB NPs (35µl) via tail vein catheter. Two hours later, the animals were anesthetized with a non-fluorinated anesthetic (ketamine/xylazine; 85/13 mg/kg) and imaged with high-resolution simultaneous 19 F/ 1 H MRI using an in-house custom dual-tuned solenoid transmit-receive coil. Simultaneous 3D 19 F/ 1 H imaging was used employing a novel steady state ultra-short echo time (UTE) technique (TE/TR=0.1ms/1.96ms) with the frequencies set to the resonance of 1 H and the CF 2 groups of the PFOB spectrum (offset 6328Hz from 19 F; representing 12 of 17 total 19 F nuclei). [42] [43] [44] [45] Using a highly oversampled 3D radial readout scheme, a series of 19 F images were reconstructed, post facto, by modifying the Nyquist weighting factor applied to samples in k-space. A Nyquist value that provided the optimal balance between the 19 F signal-to-noise ratio (SNR) and image resolution was selected and that value was uniformly applied to each individual animal [46] . 1 H images were used at the original resolution of 1.25x1.25x1.25 mm 3 . In this anesthetized rat model, neither mathematical correction nor respiratory gating were required to adjust for motion, as the breathing motion was of the same order of magnitude or less than the pixel resolution and any related ghosting was averaged out over the 28 min total scan time.
F/ 1 H MR image analysis
MR data sets were imported into ImageJ (NIH) for quantification of the 19 F signal. The method for measuring neovascularity was based upon the integral of 19 F signal intensity from α v β 3 -PFOB NPs. Lung regions of interest (ROIs) were defined from anatomical matching of multi-slice 1 H and 19 F MR datasets. These ROIs consistently included the heart in order to capture neovascularity located proximate to the trachea. To determine the background noise level, these same (size and shape) ROIs were repositioned in the upper left area of the image, devoid of any signal or potential respiratory-related ghosting. For each 19 F 2D image slice, the average signal in this background ROI was calculated and subtracted from the image to standardize. Small experiment-to-experiment differences in absolute image intensity due to variations in RF coil tuning or animal position were referenced to a PFOB emulsion standard placed with the field of view adjacent to the animal. The normalized lung 19 F signal was then averaged across all lung ROI slices.
Microscopic imaging to corroborate MR neovascular imaging
In a separate cohort (n=3/treatment) treated identically to those animals used for 19 F/ 1 H MR molecular imaging, animals were euthanized 2 hours after injection of fluorescent α v β 3 -PFOB NPs. Lungs were inflated to a pressure of 12 cmH 2 O and infused with warmed liquefied 1% agarose (42ºC). The upper airway, major bronchi, and surrounding tissue were resected and snap frozen in optimum cutting temperature (OCT) compound. Tissues were sectioned and fluorescent microscopic images (40x) were obtained with an Olympus BX61 microscope. Cell nuclei were stained blue with DAPI (4',6-diamidino-2-phenylindole, dihydrochloride).
Pharmacokinetics of α v β 3 -micelles in naive and HDM challenged Brown Norway rats
Male BN rats (100 g; n=6) were administered house dust mite allergen or PBS control by intranasal instillation on days 0, 5 and 7. On day 8, α v β 3 -micelles, incorporating 2 mole% Gd-DTPA-bisoleate as a trace marker in the surfactant commixture, were injected via tail vein. Serial blood samples were drawn for pharmacokinetic analysis 0, 5, 15, 30, 45, 60, 90 and 120 minutes post dose. Blood samples were analyzed for gadolinium using ICP OES (Optima 8000, Perkin-Elmer). The results were fit to a two compartmental model (Gd 3+ concentration = A e -αt + B e -βt ; GraphPad Prism 5.04).
Pathological response to anti-angiogenesis nanotherapy in asthmatic Brown Norway rats
Using the sensitization protocol previously discussed [34] , separate cohorts of male BN rats (BN, 125-150 g) were given HDM allergen by intranasal instillation twice/week for 3 wks. Following the second HDM treatment each week, rats received αvβ3-No-Drug, α v β 3 -Fum-PD (1.0 µmole/kg/dose), or α v β 3 -Dxtl-PD (50µl, 1.0 µmole/kg/dose) by tail vein injection (n=4 rats/group). Rats were studied one day after the last intranasal challenge of HDM.
For these animals, lungs were inflated with Z-fix (Anatech, Battle Creek, MI) to a pressure of 12 cmH 2 O for 24 hr. The left lung was divided into three sections, embedded in paraffin, and stained with hematoxylin and eosin (H&E). Airways (all cut in cross-section; max/min diameter ratio <1.5) were sized by basement membrane perimeter (ImageJ, NIH) and the number of blood vessels within the associated airway wall was enumerated. Morphometry was determined in lung sections from rats given αvβ3-No-Drug, α v β 3 -Fum-PD, or α v β 3 -Dxtl-PD micelles (n=4 rats/group).
Airway smooth muscle responsiveness following anti-angiogenesis nanotherapy
Following the same HDM and micelle dosing regimen, male BN rats (n=6/treatment group) received α v β 3 -No-Drug, α v β 3 -Fum-PD, or α v β 3 -Dxtl-PD micelles 1 day after the second weekly HDM instillation. After 3 weeks the rats were anesthetized (ketamine /xylazine, 75/5 mg/kg), intubated, and paralyzed (0.6 mg succinylcholine chloride) and dynamic respiratory mechanics were determined. Animals were ventilated (90 breaths/min; 8 ml/kg) and lung resistance and compliance were measured (Scireq Flexivent). Following the baseline measurements, cumulative dose-response relationships to methacholine chloride (MCh) aerosol (15 sec with an Aeroneb nebulizer) at challenges of 0 (PBS vehicle), 0.1, 1.0, 3.0, and 5 mg/ml MCh were obtained.
RT-PCR of endothelial specific genes following anti-angiogenesis nanotherapy
Based on previous findings and according to the same procedures [34] , CD31, an endothelial-related gene, was evaluated in large airways of HDM exposed rats given α v β 3 -No-Drug (n=3), α v β 3 -Fum-PD (n=4), or α v β 3 -Dxtl-PD (n=4) micelles. Total RNA was isolated from homogenized tracheal tissue (RNeasy;Qiagen) according to the manufacturer's protocol, cDNA was generated with QuantiTect Reverse Transcription kit (Qiagen; Real-Time PCR Detection System (Bio-Rad) settings and primers were as previously reported. [34] Bronchoalveolar lavage recovery and cytospin preparation Immediately after death, bronchoalveolar lavage (BAL) was performed using three aliquots of warm (37 o C) saline (2 ml / aliquot, 0.9% NaCl) delivered to the right lung and then gently aspirated (3-4 rats per treatment group). One ml of the recovered volume was separated and the cells were measured using a hemocytometer.
Total cell numbers were back-calculated. BAL cells (5 x10 4 ) were spun onto glass slides by cyto-centrifugation, fixed and stained with HEMA 3 STAT PACK kit (Fisher Scientific, Kalamazoo, MI). The cytospin slides were differentiated by standard cytological procedures.
FACS staining and flow cytometry of bronchoalveolar lavage cells
BAL fluid was withdrawn as described above and immediately centrifuged (1400 rpm, 5 min, 4°C). The cell pellet was resuspended in PBS for FACS staining. Dead cells were excluded using VIVID ® (Invitrogen). Cells were blocked with anti-rat CD32 (BD Pharmingen) and subjected to biotinylated anti-α v β 3 (eBioscience). Subsequent surface staining was performed using FITC anti-rat CD11c, Pacific Blue anti-rat CD11b (Bio-Rad), APC anti-rat ED-9 (eBioscience), PE anti-rat MHC II (Santa Cruz) and APC/Cy7 anti-rat CD45 (Biolegend). Cells were acquired on a BD FACSAria (BD Biosciences) and data were analyzed with FlowJo software (Tree Star, Ashland, OR).
Statistics
Imaging data were statistically analyzed using SAS (SAS Institute Inc.) using general linear models, including ANOVA and ANOCOV employing Tukey's test for multiple comparisons for significant F-statistics. Group replication was powered to detect a 50% or greater difference at an alpha level of 0.05 with a beta power of 0.80. [47] Least-squares regression was used to estimate the slopes of airway size (perimeter, mm) versus vessel number within treatment groups. Airway morphology data were analyzed with two-way ANOVA controlling for the within animal variability using Fisher's LSD for mean separation. Means with a probability of difference ≤ 0.05 were accepted as significant. All nominal data are presented as the mean ± the standard error of the mean.
Results
Fum-PD and Dxtl-PD were synthesized by modification of prior procedures as described in the Methods section and illustrated schematically in Figure 1A ,B, respectively. The α v β 3 -peptidomimetic homing ligand utilized was provided as a gift (Kereos, Inc, St. Louis). (Figure 1C ) α v β 3 -mixed micelles used for drug delivery had nominal particle sizes of 16 ± 4 nm and polydispersities between 0.1 and 0.2 based on dynamic light scattering (DLS) and an electrophoretic potential (ζ) of -20 ± 6 mV, across batches. Figure 1D presents a representative DLS distribution example for an α v β 3 -Dxtl-PD micelle formulation.
Pharmacokinetics of the α v β 3 -micelles tagged with a gadolinium-lipid tracer was studied in HDM (n=3) and naïve rats (n=3) with no difference (p>0.05) appreciated between the two groups. The results fit to a two compartmental model (Gd 3+ concentration = A e -αt + B e -βt ) were in very close agreement and were pooled to provide alpha distribution half-life of 6.9 min and a beta elimination half-life of 154.6 min estimates; the beta elimination rate unexpectedly exceeded the sampling regimen. (Figure 1E) The early induction of bronchial neovascularization after ischemic left pulmonary artery ligation and HDM sensitization was previously validated and characterized using 19 (Figure 2 D, E) Qualitatively the previously reported 19 F signal intensities of non-asthmatic control rats were similar to the control 19 F imaging data in the present study. [34] Anti-angiogenic MR molecular imaging results were corroborated by immunofluorescence microscopy. The sparse binding of the red fluorescent α v β 3 -PFOB-NP within the bronchus of an HDM rat following α v β 3 -Fum-PD micelle nanotherapy versus the dense accumulation of α v β 3 -PFOB-NP along the large airway following α v β 3 -No-Drug micelles was easily differentiated. (Figure 2 D, E) Red fluorescent α v β 3 -micelles accumulated within the HDM inflamed bronchus and surrounding parenchyma, whereas these particles administered to naïve rats (i.e., no HDM treatment) had negligible binding within or around the large pulmonary airways or vasculature. (Figure 2F ,G) Collectively, the results corroborate the tomographic changes observed with 19 F/ 1 H MR neovascular imaging with α v β 3 -PFOB NP and showed that integrin-targeted Fum-PD or Dxtl-PD micelles effectively diminished angiogenesis in HDM rats. Progressive HDM inhalation over three weeks in the Brown Norway rats was previously associated with increased (p<0.05) airway vascularity measurable with microscopy. [34] Gross airway and vascular casts demonstrated increased vascularity in HDM compared to control (PBS) rats after 3 wks of sensitization. In that study, 3 wks of HDM sensitization elicited an abundance of blood vessels within the airway wall compared to a paucity of bronchial vessels observed in the control bronchi. Striking differences in the influx of inflammatory cells, airway wall thickening, and smooth muscle contraction were noted in the HDM rats relative to the PBS controls. Further, the correlation slopes of airway size (perimeter, mm) versus the number of vessels normalized for airway area were different between HDM and PBS rats (p=0.002) and reflected increased numbers of vessels in HDM rats compared to PBS rats over an equivalent size range of airways studied (0.5-3mm).
These asthmatic changes were recapitulated at three weeks in the present study. The anti-angiogenic impact of serial αvβ3-Dxtl-PD or α v β 3 -Fum-PD micelles after HDM inhalation demonstrated by MRI on day 10 was associated with profound attenuation of airway vascularity at 21 days. Least-squares regression slopes of airway size (perimeter, mm) versus vessel number significantly differed among treatment groups (p<0.001). Control HDM rats had more vessels as revealed by the slope (4.9 ± 0.5) than those receiving αvβ3-Dxtl-PD micelles (2.7 ± 0.3) or α v β 3 -Fum-PD micelles (3.8 ± 0.5), (p<0.001). Further, the regression slope of α v β 3 -Dxtl-PD micelle response was lower than the α v β 3 -Fum-PD micelle observation. (p=0.0394). (Figure 3A ) After normalizing vessel number for airway size (i.e., diameter), both α v β 3 -Dxtl-PD (p<0.001; n=41 airways) and α v β 3 -Fum-PD (p<0.001; n=45 airways) micelles decreased vascularity to a similar extent relative to the HDM rats receiving α v β 3 -No-Drug micelles (n=55 airways). (Figure 3B) The marked morphometric vascular changes were corroborated by examining the RNA expression of endothelial-specific genes in tracheal tissue. The tracheal expression of CD31, a common biomarker of nascent and mature endothelial cells, was determined and compared to naïve tissue expression levels. (Figure 3C ) CD31 expression was markedly decreased in large airway tissue after αvβ3-Dxtl-PD and α v β 3 -Fum-PD micelle treatment compared to the HDM rats given α v β 3 -No-Drug micelles (p<0.001).
Lung functional changes, a clinical hallmark of asthma, were assessed in a separate cohort of HDM rats that received α v β 3 -Dxtl-PD, α v β 3 -Fum-PD or α v β 3 -No-Drug micelles. Respiratory system resistance (Rrs) was measured after increasing methacholine (MCh) concentrations in each group. (Figure 4A ) Airway reactivity to MCh was markedly attenuated among rats treated with α v β 3 -Dxtl-PD or α v β 3 -Fum-PD micelles compared with HDM rats receiving α v β 3 -No-Drug particles (p<0.001), which was equivalent to the resistance response reported for naive rats previously. MCh airway responsiveness did not differ between the α v β 3 -Dxtl-PD or α v β 3 -Fum-PD nanotherapies. Respiratory system compliance (Crs) in HDM rats following the 3mg MCh challenge was greater after the anti-angiogenic nanotherapies than in the α v β 3 -No-Drug micelle group (p<0.001) (Figure 4B) . Airway smooth muscle thickening correlates with response to MCh, but additional morphological measurements were not obtained to reconfirm this relationship in this study.
Bronchoalveolar (BAL) cell profiles were compared among HDM rats receiving αvβ3-No-Drug micelles versus the α v β 3 -Dxtl-PD or α v β 3 -Fum-PD micelle treatments. Total inflammatory cells recovered were similar (p>0.05) between the groups at 3 weeks. (Figure 5A ) BAL cell differential profiles among animals receiving α v β 3 -Dxtl-PD micelles had a lower (p<0.05) percentage of eosinophils compared to HDM rats receiving α v β 3 -Fum-PD or α v β 3 -No-Drug treatments. (Figure 5B ) Further, α v β 3 -Dxtl-PD nanotherapy decreased α v β 3 + CD45 + leukocytes (p<0.001) whereas α v β 3 -Fum-PD and α v β 3 -No-Drug treatments had no effect. (Figure 5C ) BAL flow cytometry showed that both α v β 3 -Fum-PD and α v β 3 -Dxtl-PD micelle treatments decreased (p<0.001) α v β 3 + macrophage/monocyte numbers versus the control micelles ( Figure 5D) . A. Least-squares regression slopes of airway size (perimeter, mm) versus vessel number significantly differed among treatment groups (p<0.001). Control HDM (•) rats receiving αvβ3-No-Drug had more blood vessels as revealed by the slope (4.9 ± 0.5) than those receiving αvβ3-Dxtl-PD micelles (2.7 ± 0.3, ◻) or αvβ3-Fum-PD micelles (3.8 ± 0.5, ▲), (p<0.001). Further, the regression slope of αvβ3-Dxtl-PD micelle response was lower than the αvβ3-Fum-PD micelle observation. (p=0.0394). B. After normalizing vessel number for airway size (i.e., diameter), both αvβ3-Dxtl-PD (p<0.0001) and αvβ3-Fum-PD (p<0.0003) micelles decreased vascularity to a similar extent relative to the HDM rats receiving αvβ3-No-Drug micelles (n=4 rats/group; 2-way ANOVA and Fisher's LSD). C. CD31 expression in the trachea of the three treatment groups compared to naïve tissue. Gene expression for CD31, a common endothelial cell marker, was markedly decreased in large airway tissue (trachea) after αvβ3-Dxtl-PD and αvβ3-Fum-PD compared to αvβ3-No-Drug (p=0.0005). 
Discussion
Structural remodeling of asthmatic airways has long been associated with microvascular expansion of the capillary bed. Although angiogenesis is a hallmark feature of asthmatic inflammatory responses, specific therapeutic anti-angiogenesis interventions have not been considered. In the present studies, anti-angiogenic prodrug therapeutics delivered by a micelle therapy markedly suppressed microvascularity, bronchial remodeling, and airway hyper-responsiveness in HDM rats, suggesting for the first time that direct anti-neovascular therapy can contribute significantly to asthma management.
The bioactivity and effectiveness of Sn2 lipase labile prodrugs of Dxtl and Fum delivered via αvβ3-integrin targeted micelles in HDM rats was definitively demonstrated noninvasively with 19 F/ 1 H MR neovascular molecular imaging using vascular-constrained α v β 3 -PFOB nanoparticles and a clinical 3T scanner. The spatial and temporal character of neovascular expansion within the upper airways/bronchi of the HDM rats given α v β 3 -No-Drug micelles recapitulated the 19 F/ 1 H MR response previously reported at this field strength. [34] However, the neovascular signal among rats receiving α v β 3 -Dxtl-PD micelles or α v β 3 -Fum-PD was greatly reduced, validating that the prodrugs retained drug bioactivity and that α v β 3 -micelles effectively homed and bound to the neovasculature. These 19 F/ 1 H MR imaging results were corroborated by immunofluorescent microscopic studies that also delineated the differential targeting of fluorescent α v β 3 -PFOB nanoparticles (red) in HDM rats receiving α v β 3 -No-Drug and α v β 3 -Dxtl-PD micelles. The targeting of fluorescent α v β 3 -micelles (red) into the airway wall and local surrounding tissue in No-Drug treated HDM rats but not in naïve animals is congruent with the therapeutic effects measured.
Within this study, MR provided early recognition of HDM induced airway inflammation as reflected by neovascular expansion and provided a quantitative read-out of anti-angiogenic treatment response. In the broader context, this result and previous reports of clinical 19 F/ 1 H MR molecular imaging of the lung pose the prospect for more detailed and quantitative image guided management of asthma patients, particularly those with moderate to severe disease. The workhorse imaging modality of lung imaging is computed tomography (CT) and for cancer is positron emission tomography/CT (PET/CT). As healthcare costs associated with newer biological precision medicine therapies soar for patients with moderate and particularly severe asthma, improved high-sensitivity noninvasive nonionizing imaging to optimize and minimize the use of these therapies will be welcome. [48] [49] [50] [51] Anticipating that repeat imaging studies will be used in pediatric patients as well as adults, the implementation of MRI techniques becomes highly attractive and circumvents potential cumulative X-ray risks.
Increased vascular density in the sub-epithelial submucosa of the lungs of asthmatic patients as well as other bronchial vasculature abnormalities is well documented and associated with increased blood flow and edematous airway thickening. [52] After 3 weeks of biweekly HDM challenges, morphometric measurements of airway size (perimeter) and vessel number revealed classic asthma-related vascular expansion in the HDM rats receiving αvβ3-No-Drug micelles. HDM rats given the anti-angiogenic α v β 3 -Dxtl-PD or α v β 3 -Fum-PD micelle therapies had dramatically less microvascularity, which was confirmed by reduced CD31 RNA expression in these animals compared to the α v β 3 -No-Drug controls.
Increased vascularization was previously correlated with airflow limitation and bronchial hyper-responsiveness. [12, 53, 54] In the present study, MCh induced respiratory system resistance (Rrs) was high in the HDM rats receiving the αvβ3-No-Drug particles but markedly and equivalently attenuated among rats treated with α v β 3 -Dxtl-PD or α v β 3 -Fum-PD micelles. Similarly, respiratory system compliance (Crs) was increased among HDM rats exposed to anti-angiogenic prodrug nanotherapy compared with the No-Drug micelles. Clearly, the relationship between airway hyper-responsiveness and vascularity observed in patients was observed in the HDM rat model, and by extension the substantial improvements elicited by αvβ3-Dxtl-PD or α v β 3 -Fum-PD micelles in HDM rats could reasonably translate into patients.
As expected, microscopic examination revealed marked increases in inflammatory cells in HDM rat airways and surrounding tissues that were not appreciated in the lungs from control animals. Increased αvβ3-integrin expression heavily co-localized with activated macrophages by microscopy was also appreciated in BAL cells of control HDM. However, α v β 3 + macrophages were significantly reduced by both targeted nanotherapies and significantly more so by the α v β 3 -Dxtl-PD micelle treatment. Anti-angiogenic therapy is typically viewed from the perspective of neovasculature pruning, but recent studies intensively examining the effects of α v β 3 -Fum-PD in inflammatory mouse models have shown that direct anti-angiogenesis therapy is also anti-inflammatory. [24] Fumagillin is well known to impact the proliferation of neovascular endothelial cells, but this mycotoxin has negligible effects on non-endothelial cell types. [55] The overall outcome of a series of detailed experiments to delineate the potential mechanism for local inflammation suppression with integrin-targeted fumagillin determined that endothelial nitric oxide (NO) derived and released from the drug-targeted neoendothelial cells modulated local macrophage inflammatory response through AMP-activated protein kinase (AMPK). NO-induced AMPK activation decreased the mammalian target of rapamycin (mTOR) activity and increased autophagic flux, as evidenced by p62 depletion and increased autolysosome formation. Increased macrophage autophagy flux was associated with degradation of IkappaB kinase (IKK), suppression of the NF-ĸB-p65 signaling pathway, and ultimately decreased inflammatory cytokine release. [24] Thus, the anti-inflammatory impact of Fum-PD was indirectly mediated through the endothelial NO release with suppressive feedback on the local macrophages.
αvβ3-micelles, similar in size to IgG antibodies, penetrate into inflamed tissue readily. These micelles can home and bind to extravascular targets [56] , including macrophages expressing activated α v β 3 -integrin.
Fum-PD is ineffective when co-incubated with activated macrophages in culture, but it is effective against vascular tubule formation in vitro. [24, 57] Dxtl-PD can suppress macrophage inflammatory cytokine release in vitro and in vivo, as well as being anti-angiogenic [30] (Supporting Information: S1). In the present study, αvβ3-Dxtl-PD micelles, in addition to the anti-angiogenic anti-inflammatory effects elicited by targeting neoendothelial cells similar to α v β 3 -Fum-PD micelles, they likely bound phagocytic cells, possibly the M2 phenotype macrophages increased in antigen-induced asthma. Of note in breast cancer, M2 macrophages uniquely express activated αvβ3-integrin. [58] α v β 3 -Dxtl-PD micelles but not α v β 3 -Fum-PD micelles reduced BAL α v β 3 + CD45 + cells, probably as a direct consequence of targeted taxane prodrug delivery. This would be expected due to the endothelial cellular specificity of fumagillin. BAL eosinophils were generally elevated in the HDM rats, but markedly reduced among animals receiving αvβ3-Dxtl-PD micelles and not the α v β 3 -Fum-PD micelles. Since α v β 3 -integrin expression by eosinophils is uncommon, we hypothesize that the reduction of eosinophils was related to α v β 3 -Dxtl-PD impacting M2 macrophages within a complex Th1/Th2-macrophage-eosinophil cross-talk network.
[ [59] [60] [61] Further delineation of these complex interrelationships is beyond the scope of this initial study.
While the present report has shown for the first time that targeted α v β 3 -micelle nanotherapy can ameliorate bronchial airway hyper-reactivity and inflammatory characteristics of dust-mite induced asthma in rats, specific mechanistic studies will be required to deconvolve the disruption of the complex roles of cellular inflammatory components and chemokines involved in the pathologic remodeling within the inflamed airways. Further, these data demonstrate that HDM induced asthma can be approached in a nontraditional therapeutic fashion, additional research to optimize the pharmacology and to elucidate the safety of this targeted therapeutic micelle approach is warranted.
Conclusion
The results of this study clearly indicate that direct anti-angiogenesis therapy with α v β 3 -Dxtl-PD or α v β 3 -Fum-PD micelles can ameliorate asthma in the house dust mite triggered Brown Norway rat model. Airway hyper-responsiveness and increased microvascularity, classic hallmarks of asthma, were significantly reduced with these treatments. Whereas the dogma of efficacy surrounding anti-angiogenesis therapy has been associated with the impact of vascular pruning, in the current study αvβ3-Dxtl-PD or α v β 3 -Fum-PD micelles treatment of proliferating neoendothelial cells led to secondary anti-inflammatory benefits.
